StockData
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. (MBRX) stock

MBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$6.75−0.08 (-1.17%)

Close on Nov 18, 2026Market cap $131.47MP/E –Yield –

Moleculin Biotech revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Moleculin Biotech's revenue for the twelve months ending Jun 30, 2026 was $0. For fiscal 2025 it was $0. The highest annual figure on record is $0 in fiscal 2016.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0–
FY2024Dec 31, 2024$0–
FY2023Dec 31, 2023$0–
FY2022Dec 31, 2022$0–
FY2021Dec 31, 2021$0–
FY2020Dec 31, 2020$0–
FY2019Dec 31, 2019$0–
FY2018Dec 31, 2018$0–
FY2017Dec 31, 2017$0–
FY2016Dec 31, 2016$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0–
Q1 FY2026Mar 31, 2026$0–
Q4 FY2025Dec 31, 2025$0–
Q3 FY2025Sep 30, 2025$0–
Q2 FY2025Jun 30, 2025$0–
Q1 FY2025Mar 31, 2025$0–
Q4 FY2024Dec 31, 2024$0–
Q3 FY2024Sep 30, 2024$0–
Q2 FY2024Jun 30, 2024$0–
Q1 FY2024Mar 31, 2024$0–
Q4 FY2023Dec 31, 2023$0–
Q3 FY2023Sep 30, 2023$0–
Q2 FY2023Jun 30, 2023$0–
Q1 FY2023Mar 31, 2023$0–
Q4 FY2022Dec 31, 2022$0–
Q3 FY2022Sep 30, 2022$0–
Q2 FY2022Jun 30, 2022$0–
Q1 FY2022Mar 31, 2022$0–
Q4 FY2021Dec 31, 2021$0–
Q3 FY2021Sep 30, 2021$0–
Q2 FY2021Jun 30, 2021$0–
Q1 FY2021Mar 31, 2021$0–
Q4 FY2020Dec 31, 2020$0–
Q3 FY2020Sep 30, 2020$0–
Q2 FY2020Jun 30, 2020$0–
Q1 FY2020Mar 31, 2020$0–
Q4 FY2019Dec 31, 2019$0–
Q3 FY2019Sep 30, 2019$0–
Q2 FY2019Jun 30, 2019$0–
Q1 FY2019Mar 31, 2019$0–
Q4 FY2018Dec 31, 2018$0–
Q3 FY2018Sep 30, 2018$0–
Q2 FY2018Jun 30, 2018$0–
Q1 FY2018Mar 31, 2018$0–
Q4 FY2017Dec 31, 2017$0–
Q3 FY2017Sep 30, 2017$0–
Q4 FY2016Dec 31, 2016$0–
Q3 FY2016Sep 30, 2016$0–
Q2 FY2016Jun 30, 2016$0–

More Moleculin Biotech figures

See a number that looks wrong?